Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Eyebright Medical to Acquire Control of Delta Medical in $143 M Sports‑Medicine Deal

Fineline Cube Jan 22, 2026
Company Deals

Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal

Fineline Cube Jan 20, 2026
Company Deals

Shionogi Boosts ViiV Stake to 21.7% in $2.1 Billion Deal, Doubles Down on HIV Focus

Fineline Cube Jan 20, 2026
Company Deals Medical Device

EasyDiagnosis Bio to Acquire 51% of Ailex Medical in $5.1M Deal, Gains IVD Platform

Fineline Cube Jan 20, 2026
Company Deals

AstraZeneca Secures Full Global Rights to AbelZeta’s C‑CAR031 in $630M CAR‑T Deal

Fineline Cube Jan 20, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Drug

Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors

Fineline Cube Jan 22, 2026
Company Drug

Biokin’s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World’s First EGFR×HER3 Bispecific

Fineline Cube Jan 22, 2026
Company Deals

Aiolos Bio Inc. Raises USD 245 Million in Series A Funding Led by Top Investors

Fineline Cube Oct 26, 2023

Aiolos Bio Inc., a US-based biotech company, has officially launched with the successful completion of...

Company Drug

Qilu Pharmaceutical Unveils Promising Data for QL1706 in Cervical Cancer Treatment at ESMO 2023

Fineline Cube Oct 26, 2023

China’s Qilu Pharmaceutical showcased compelling data for its combination drug QL1706 (iparomlimab and tuvonralimab) as...

Company

Medytox Shifts Strategy for China Market Entry with Next-Generation Botulinum Toxin

Fineline Cube Oct 26, 2023

Korea-based biopharmaceutical company Medytox has reportedly revamped its strategy for entering the Chinese market, according...

Company Medical Device

MicroPort MedBot’s Toumai Robot Gains NMPA Approval for Endoscopic Surgery

Fineline Cube Oct 26, 2023

Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252), a leading medical robotics company, has announced...

Company

Danaher Corporation Reports Q3 2023 Earnings with 10.5% Global Revenue Decline

Fineline Cube Oct 26, 2023

US-based science and tech services giant Danaher Corporation (NYSE: DHR) has reported its Q3 2023...

Company Deals

AstraZeneca Licenses Nanoform’s Starmap AI Platform to Enhance Drug Development

Fineline Cube Oct 25, 2023

UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has obtained a license from Finnish drug design...

Company Drug

EC Approves AstraZeneca and Daiichi Sankyo’s Enhertu for Advanced HER2+ NSCLC

Fineline Cube Oct 25, 2023

The European Commission (EC) has granted registration approval for the HER2-directed antibody-drug conjugate (ADC) Enhertu...

Company Drug

Dizal’s Sunvozertinib Shows Promising Efficacy in Advanced NSCLC at ESMO 2023

Fineline Cube Oct 25, 2023

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) presented compelling efficacy and safety data for its...

Company Deals Drug

AbbVie Partners with Lupus Therapeutics to Advance Rinvoq in SLE Treatment

Fineline Cube Oct 25, 2023

AbbVie (NYSE: ABBV) announced this week a strategic collaboration with US-based Lupus Therapeutics aimed at...

Company Drug

BMS’s BMS-986278 Receives FDA Breakthrough Therapy Designation for Pulmonary Fibrosis

Fineline Cube Oct 25, 2023

Bristol-Myers Squibb (BMS; NYSE: BMY) announced this week that it has received breakthrough therapy designation...

Company

Novartis Q3 Earnings Reflect Strong Growth Post-Sandoz Spinoff

Fineline Cube Oct 25, 2023

Novartis (NYSE: NVS) has released its Q3 2023 financial results, marking the first report since...

Company Drug

Fosun Pharma Gains NMPA Approval for Phase I Trial of XS-03 in Advanced Solid Tumors

Fineline Cube Oct 25, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196), a leading healthcare conglomerate in China, has...

Company Drug

Cutia Therapeutics’ CU-20401 Completes Phase I Study for Obesity Treatment

Fineline Cube Oct 25, 2023

China-based dermatology specialist Cutia Therapeutics (HKG: 2487) has announced the last subject out (LSO) in...

Hospital Policy / Regulatory

Peking University Unveils National Standardized Pain Treatment Center in China

Fineline Cube Oct 25, 2023

Peking University People’s Hospital has officially unveiled the plaque for the National Standardized Pain Treatment...

Company Deals

Leadinno Medical Valley Secures Series A+ Funding for Neuroregulation Device R&D

Fineline Cube Oct 25, 2023

Leadinno Medical Valley, a Beijing-based innovator in pain management and neuroregulation devices, has reportedly secured...

Company Drug

China Grand Pharma Initiates Phase III Trial for GPN00833 in Cataract Surgery Recovery

Fineline Cube Oct 25, 2023

China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced a significant milestone...

Company Deals

Gates Foundation Funds CanSino’s Innovative Polio Vaccine Development

Fineline Cube Oct 25, 2023

The Bill & Melinda Gates Foundation has announced a commitment of USD 2 million to...

Company Deals

OrbiMed Raises Over USD 4.3 Billion for Private Investment Funds Focused on Healthcare

Fineline Cube Oct 25, 2023

US-based investment fund giant OrbiMed has announced the successful raising of over USD 4.3 billion...

Company Deals

BMS Regains Full Rights to Mavacamten in China and Asia from LianBio

Fineline Cube Oct 25, 2023

Bristol-Myers Squibb (BMS; NYSE: BMY) is set to regain full control of mavacamten, a treatment...

Company Drug

Sihuan Pharmaceutical Gains NMPA Approval for Innovative Type 2 Diabetes Treatment

Fineline Cube Oct 25, 2023

China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced that it has received clinical...

Posts pagination

1 … 400 401 402 … 612

Recent updates

  • Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors
  • Biokin’s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World’s First EGFR×HER3 Bispecific
  • Kawin Technology Withdraws Hepatitis B Filing for Peginterferon Alfacon‑2 After NMPA Feedback
  • Eyebright Medical to Acquire Control of Delta Medical in $143 M Sports‑Medicine Deal
  • AstraZeneca to Delist from Nasdaq, Shift Direct NYSE Listing in Share Structure Unification
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors

Company Drug

Biokin’s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World’s First EGFR×HER3 Bispecific

Company Drug

Kawin Technology Withdraws Hepatitis B Filing for Peginterferon Alfacon‑2 After NMPA Feedback

Company Deals

Eyebright Medical to Acquire Control of Delta Medical in $143 M Sports‑Medicine Deal

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.